ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Vaccine for Influenza Market Research Report 2025
Published Date: 2025-12-26
|
Report Code: QYRE-Auto-3B8011
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Vaccine for Influenza Market Insights Forecast to 2028
BUY CHAPTERS

Global Vaccine for Influenza Market Research Report 2025

Code: QYRE-Auto-3B8011
Report
2025-12-26
Pages:124
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Sanofi
CSL Limited
GSK
Astrazeneca plc
Viatris
Hualan Bio
Changchun Institute of Biological
Sinovac
BCHT
Jiangsu GDK
KM Biologics

Vaccine for Influenza Market Size

The global market for Vaccine for Influenza was valued at US$ 8955 million in the year 2024 and is projected to reach a revised size of US$ 12993 million by 2031, growing at a CAGR of 5.5% during the forecast period.

Vaccine for Influenza Market

Vaccine for Influenza Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Vaccine for Influenza competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
The Influenza Vaccine is a biological product designed to stimulate the human immune system to produce virus-specific antibodies, thereby preventing seasonal influenza infection and reducing the risks of severe illness, complications, and mortality. Its mechanism relies on inactivated, attenuated, recombinant, or genetically engineered antigen delivery technologies that safely induce protective immune memory. As one of the most strategic public-health tools worldwide, influenza vaccines are incorporated into national immunization programs or prioritized recommendations by health authorities to lower disease burden, reduce healthcare utilization, and protect high-risk populations such as the elderly, patients with chronic conditions, pregnant women, and children. With continuous viral mutation and strengthened global surveillance, influenza vaccines are undergoing ongoing innovation in formulation updates, platform technologies, strain-matching optimization, and production efficiency, thereby supporting population health, medical cost containment, and sustainable industry growth.In 2024, global Vaccine for Influenza production reached approximately 845.8 m units, with an average global market price of around US$ 10.8 perunit.The average gross profit margin of this product is 56%.
The strengthening of global public-health systems is transforming influenza vaccines from “seasonal demand products” into “fundamental health-protection tools.” Governments are increasing investment in preventive medicine, expanding immunization coverage, and enhancing protection for key populations, creating stable demand momentum. Annual reports of major vaccine companies highlight continuous upgrades in mRNA, recombinant protein, and adjuvant-enhanced platforms, improving antigenicity, production speed, and strain-matching accuracy. Regulatory reforms in approval pathways, manufacturing upgrades, and international harmonization are enhancing supply-chain resilience. As enterprises, healthcare institutions, and insurers increasingly recognize the economic impact of influenza peaks, vaccines are positioned as the most cost-effective preventive solution, supporting long-term growth.
The industry faces uncertainties due to continuous viral mutation, requiring ongoing strain adaptation and formulation updates that increase R&D and manufacturing pressure. In some countries, limited public awareness or high out-of-pocket vaccination costs lead to fluctuating uptake rates. The reliance on specific upstream materials and specialized manufacturing equipment means that global logistics, regulatory adjustments, or regional policy changes can impact capacity deployment. Annual reports also indicate intensified competition, with novel technology platforms entering rapidly, forcing traditional manufacturers to invest heavily in R&D and production upgrades. Differing cold-chain standards across countries add further complexity to cross-border distribution.
Demand is shifting from “seasonal vaccination” to “routine immunization management,” particularly among high-risk groups such as the elderly, respiratory-disease patients, and healthcare workers. Hospitals, schools, and large enterprises increasingly adopt centralized procurement to mitigate the operational impact during influenza peaks. With rising consumer awareness, quadrivalent vaccines, high-immunogenicity formulations, preservative-free products, and next-generation platforms are seeing faster penetration. Expanded deployment of community clinics, pharmacies, and mobile vaccination points is improving accessibility. Corporate and insurance-driven population-health programs are also steering demand toward higher-quality vaccines.
Key upstream inputs include seed viruses, cell substrates, specialized culture media, adjuvant systems, and sterile-filling consumables, with global suppliers relatively concentrated. Annual reports show that advanced platforms require higher purity, stability, and consistency in antigen and adjuvant materials, increasing the technological intensity and quality sensitivity of the supply chain. As egg-based, cell-based, and recombinant systems evolve in parallel, differences in raw materials have a direct impact on process efficiency and capacity scalability. Requirements for cold-chain packaging, quality-control reagents, and testing consumables are also rising, pushing the upstream ecosystem toward higher standards and broader internationalization.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Vaccine for Influenza, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vaccine for Influenza.
The Vaccine for Influenza market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Vaccine for Influenza market comprehensively. Regional market sizes, concerning products by Type, by Application, by Technology and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Vaccine for Influenza manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, by Technology and by regions.

Scope of Vaccine for Influenza Market Report

Report Metric Details
Report Name Vaccine for Influenza Market
Accounted market size in year US$ 8955 million
Forecasted market size in 2031 US$ 12993 million
CAGR 5.5%
Base Year year
Forecasted years 2026 - 2031
Segment by Type
  • Trivalent Influenza Vaccine
  • Quadrivalent Influenza Vaccine
Segment by Technology
  • Chicken Embryo Technology
  • Cell Culture Technology
  • Recombinant Technology
  • Adjuvant Vaccines
Segment by Administration
  • Injectable
  • Nasal Spray
Segment by Application
  • 6 Months to 3 Years
  • > 3 Years
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Sanofi, CSL, GSK, Viatris, AstraZeneca, Hualan Bio, Changchun Institute of Biological, Sinovac, BCHT, Jiangsu GDK, KM Biologics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Vaccine for Influenza manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Vaccine for Influenza in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Vaccine for Influenza Market growing?

Ans: The Vaccine for Influenza Market witnessing a CAGR of 5.5% during the forecast period 2026-2031.

What is the Vaccine for Influenza Market size in 2031?

Ans: The Vaccine for Influenza Market size in 2031 will be US$ 12993 million.

Who are the main players in the Vaccine for Influenza Market report?

Ans: The main players in the Vaccine for Influenza Market are Sanofi, CSL, GSK, Viatris, AstraZeneca, Hualan Bio, Changchun Institute of Biological, Sinovac, BCHT, Jiangsu GDK, KM Biologics

What are the Application segmentation covered in the Vaccine for Influenza Market report?

Ans: The Applications covered in the Vaccine for Influenza Market report are 6 Months to 3 Years, > 3 Years

What are the Type segmentation covered in the Vaccine for Influenza Market report?

Ans: The Types covered in the Vaccine for Influenza Market report are Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine

1 Vaccine for Influenza Market Overview
1.1 Product Definition
1.2 Vaccine for Influenza by Type
1.2.1 Global Vaccine for Influenza Market Value Comparison by Type (2024 VS 2031)
1.2.2 Trivalent Influenza Vaccine
1.2.3 Quadrivalent Influenza Vaccine
1.3 Vaccine for Influenza by Technology
1.3.1 Global Vaccine for Influenza Market Value Comparison by Technology: 2024 VS 2031
1.3.2 Chicken Embryo Technology
1.3.3 Cell Culture Technology
1.3.4 Recombinant Technology
1.3.5 Adjuvant Vaccines
1.4 Vaccine for Influenza by Administration
1.4.1 Global Vaccine for Influenza Market Value Comparison by Administration: 2024 VS 2031
1.4.2 Injectable
1.4.3 Nasal Spray
1.5 Vaccine for Influenza by Application
1.5.1 Global Vaccine for Influenza Market Value by Application (2024 VS 2031)
1.5.2 6 Months to 3 Years
1.5.3 > 3 Years
1.6 Global Vaccine for Influenza Market Size Estimates and Forecasts
1.6.1 Global Vaccine for Influenza Revenue 2020-2031
1.6.2 Global Vaccine for Influenza Sales 2020-2031
1.6.3 Global Vaccine for Influenza Market Average Price (2020-2031)
1.7 Assumptions and Limitations
2 Vaccine for Influenza Market Competition by Manufacturers
2.1 Global Vaccine for Influenza Sales Market Share by Manufacturers (2020-2025)
2.2 Global Vaccine for Influenza Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Vaccine for Influenza Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Vaccine for Influenza, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Vaccine for Influenza, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Vaccine for Influenza, Product Type & Application
2.7 Global Key Manufacturers of Vaccine for Influenza, Date of Enter into This Industry
2.8 Global Vaccine for Influenza Market Competitive Situation and Trends
2.8.1 Global Vaccine for Influenza Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Vaccine for Influenza Players Market Share by Revenue
2.8.3 Global Vaccine for Influenza Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Vaccine for Influenza Market Scenario by Region
3.1 Global Vaccine for Influenza Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Vaccine for Influenza Sales by Region: 2020-2031
3.2.1 Global Vaccine for Influenza Sales by Region: 2020-2025
3.2.2 Global Vaccine for Influenza Sales by Region: 2026-2031
3.3 Global Vaccine for Influenza Revenue by Region: 2020-2031
3.3.1 Global Vaccine for Influenza Revenue by Region: 2020-2025
3.3.2 Global Vaccine for Influenza Revenue by Region: 2026-2031
3.4 North America Vaccine for Influenza Market Facts & Figures by Country
3.4.1 North America Vaccine for Influenza Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Vaccine for Influenza Sales by Country (2020-2031)
3.4.3 North America Vaccine for Influenza Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Vaccine for Influenza Market Facts & Figures by Country
3.5.1 Europe Vaccine for Influenza Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Vaccine for Influenza Sales by Country (2020-2031)
3.5.3 Europe Vaccine for Influenza Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Vaccine for Influenza Market Facts & Figures by Region
3.6.1 Asia Pacific Vaccine for Influenza Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Vaccine for Influenza Sales by Region (2020-2031)
3.6.3 Asia Pacific Vaccine for Influenza Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Vaccine for Influenza Market Facts & Figures by Country
3.7.1 Latin America Vaccine for Influenza Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Vaccine for Influenza Sales by Country (2020-2031)
3.7.3 Latin America Vaccine for Influenza Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Vaccine for Influenza Market Facts & Figures by Country
3.8.1 Middle East and Africa Vaccine for Influenza Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Vaccine for Influenza Sales by Country (2020-2031)
3.8.3 Middle East and Africa Vaccine for Influenza Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Vaccine for Influenza Sales by Type (2020-2031)
4.1.1 Global Vaccine for Influenza Sales by Type (2020-2025)
4.1.2 Global Vaccine for Influenza Sales by Type (2026-2031)
4.1.3 Global Vaccine for Influenza Sales Market Share by Type (2020-2031)
4.2 Global Vaccine for Influenza Revenue by Type (2020-2031)
4.2.1 Global Vaccine for Influenza Revenue by Type (2020-2025)
4.2.2 Global Vaccine for Influenza Revenue by Type (2026-2031)
4.2.3 Global Vaccine for Influenza Revenue Market Share by Type (2020-2031)
4.3 Global Vaccine for Influenza Price by Type (2020-2031)
5 Segment by Application
5.1 Global Vaccine for Influenza Sales by Application (2020-2031)
5.1.1 Global Vaccine for Influenza Sales by Application (2020-2025)
5.1.2 Global Vaccine for Influenza Sales by Application (2026-2031)
5.1.3 Global Vaccine for Influenza Sales Market Share by Application (2020-2031)
5.2 Global Vaccine for Influenza Revenue by Application (2020-2031)
5.2.1 Global Vaccine for Influenza Revenue by Application (2020-2025)
5.2.2 Global Vaccine for Influenza Revenue by Application (2026-2031)
5.2.3 Global Vaccine for Influenza Revenue Market Share by Application (2020-2031)
5.3 Global Vaccine for Influenza Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Company Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Vaccine for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Sanofi Vaccine for Influenza Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 CSL
6.2.1 CSL Company Information
6.2.2 CSL Description and Business Overview
6.2.3 CSL Vaccine for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.2.4 CSL Vaccine for Influenza Product Portfolio
6.2.5 CSL Recent Developments/Updates
6.3 GSK
6.3.1 GSK Company Information
6.3.2 GSK Description and Business Overview
6.3.3 GSK Vaccine for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.3.4 GSK Vaccine for Influenza Product Portfolio
6.3.5 GSK Recent Developments/Updates
6.4 Viatris
6.4.1 Viatris Company Information
6.4.2 Viatris Description and Business Overview
6.4.3 Viatris Vaccine for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Viatris Vaccine for Influenza Product Portfolio
6.4.5 Viatris Recent Developments/Updates
6.5 AstraZeneca
6.5.1 AstraZeneca Company Information
6.5.2 AstraZeneca Description and Business Overview
6.5.3 AstraZeneca Vaccine for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.5.4 AstraZeneca Vaccine for Influenza Product Portfolio
6.5.5 AstraZeneca Recent Developments/Updates
6.6 Hualan Bio
6.6.1 Hualan Bio Company Information
6.6.2 Hualan Bio Description and Business Overview
6.6.3 Hualan Bio Vaccine for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Hualan Bio Vaccine for Influenza Product Portfolio
6.6.5 Hualan Bio Recent Developments/Updates
6.7 Changchun Institute of Biological
6.7.1 Changchun Institute of Biological Company Information
6.7.2 Changchun Institute of Biological Description and Business Overview
6.7.3 Changchun Institute of Biological Vaccine for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Changchun Institute of Biological Vaccine for Influenza Product Portfolio
6.7.5 Changchun Institute of Biological Recent Developments/Updates
6.8 Sinovac
6.8.1 Sinovac Company Information
6.8.2 Sinovac Description and Business Overview
6.8.3 Sinovac Vaccine for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Sinovac Vaccine for Influenza Product Portfolio
6.8.5 Sinovac Recent Developments/Updates
6.9 BCHT
6.9.1 BCHT Company Information
6.9.2 BCHT Description and Business Overview
6.9.3 BCHT Vaccine for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.9.4 BCHT Vaccine for Influenza Product Portfolio
6.9.5 BCHT Recent Developments/Updates
6.10 Jiangsu GDK
6.10.1 Jiangsu GDK Company Information
6.10.2 Jiangsu GDK Description and Business Overview
6.10.3 Jiangsu GDK Vaccine for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Jiangsu GDK Vaccine for Influenza Product Portfolio
6.10.5 Jiangsu GDK Recent Developments/Updates
6.11 KM Biologics
6.11.1 KM Biologics Company Information
6.11.2 KM Biologics Description and Business Overview
6.11.3 KM Biologics Vaccine for Influenza Sales, Revenue and Gross Margin (2020-2025)
6.11.4 KM Biologics Vaccine for Influenza Product Portfolio
6.11.5 KM Biologics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Vaccine for Influenza Industry Chain Analysis
7.2 Vaccine for Influenza Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Vaccine for Influenza Production Mode & Process Analysis
7.4 Vaccine for Influenza Sales and Marketing
7.4.1 Vaccine for Influenza Sales Channels
7.4.2 Vaccine for Influenza Distributors
7.5 Vaccine for Influenza Customer Analysis
8 Vaccine for Influenza Market Dynamics
8.1 Vaccine for Influenza Industry Trends
8.2 Vaccine for Influenza Market Drivers
8.3 Vaccine for Influenza Market Challenges
8.4 Vaccine for Influenza Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Sanofi
CSL Limited
GSK
Astrazeneca plc
Viatris
Hualan Bio
Changchun Institute of Biological
Sinovac
BCHT
Jiangsu GDK
KM Biologics
List of Tables
 Table 1. Global Vaccine for Influenza Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Vaccine for Influenza Market Value by Technology, (US$ Million) & (2024 VS 2031)
 Table 3. Global Vaccine for Influenza Market Value by Administration, (US$ Million) & (2024 VS 2031)
 Table 4. Global Vaccine for Influenza Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 5. Global Vaccine for Influenza Market Competitive Situation by Manufacturers in 2024
 Table 6. Global Vaccine for Influenza Sales (M Units) of Key Manufacturers (2020-2025)
 Table 7. Global Vaccine for Influenza Sales Market Share by Manufacturers (2020-2025)
 Table 8. Global Vaccine for Influenza Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 9. Global Vaccine for Influenza Revenue Share by Manufacturers (2020-2025)
 Table 10. Global Market Vaccine for Influenza Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 11. Global Key Players of Vaccine for Influenza, Industry Ranking, 2022 VS 2023 VS 2024
 Table 12. Global Key Manufacturers of Vaccine for Influenza, Manufacturing Sites & Headquarters
 Table 13. Global Key Manufacturers of Vaccine for Influenza, Product Type & Application
 Table 14. Global Key Manufacturers of Vaccine for Influenza, Date of Enter into This Industry
 Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 16. Global Vaccine for Influenza by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaccine for Influenza as of 2024)
 Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 18. Global Vaccine for Influenza Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 19. Global Vaccine for Influenza Sales by Region (2020-2025) & (M Units)
 Table 20. Global Vaccine for Influenza Sales Market Share by Region (2020-2025)
 Table 21. Global Vaccine for Influenza Sales by Region (2026-2031) & (M Units)
 Table 22. Global Vaccine for Influenza Sales Market Share by Region (2026-2031)
 Table 23. Global Vaccine for Influenza Revenue by Region (2020-2025) & (US$ Million)
 Table 24. Global Vaccine for Influenza Revenue Market Share by Region (2020-2025)
 Table 25. Global Vaccine for Influenza Revenue by Region (2026-2031) & (US$ Million)
 Table 26. Global Vaccine for Influenza Revenue Market Share by Region (2026-2031)
 Table 27. North America Vaccine for Influenza Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. North America Vaccine for Influenza Sales by Country (2020-2025) & (M Units)
 Table 29. North America Vaccine for Influenza Sales by Country (2026-2031) & (M Units)
 Table 30. North America Vaccine for Influenza Revenue by Country (2020-2025) & (US$ Million)
 Table 31. North America Vaccine for Influenza Revenue by Country (2026-2031) & (US$ Million)
 Table 32. Europe Vaccine for Influenza Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 33. Europe Vaccine for Influenza Sales by Country (2020-2025) & (M Units)
 Table 34. Europe Vaccine for Influenza Sales by Country (2026-2031) & (M Units)
 Table 35. Europe Vaccine for Influenza Revenue by Country (2020-2025) & (US$ Million)
 Table 36. Europe Vaccine for Influenza Revenue by Country (2026-2031) & (US$ Million)
 Table 37. Asia Pacific Vaccine for Influenza Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 38. Asia Pacific Vaccine for Influenza Sales by Region (2020-2025) & (M Units)
 Table 39. Asia Pacific Vaccine for Influenza Sales by Region (2026-2031) & (M Units)
 Table 40. Asia Pacific Vaccine for Influenza Revenue by Region (2020-2025) & (US$ Million)
 Table 41. Asia Pacific Vaccine for Influenza Revenue by Region (2026-2031) & (US$ Million)
 Table 42. Latin America Vaccine for Influenza Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Latin America Vaccine for Influenza Sales by Country (2020-2025) & (M Units)
 Table 44. Latin America Vaccine for Influenza Sales by Country (2026-2031) & (M Units)
 Table 45. Latin America Vaccine for Influenza Revenue by Country (2020-2025) & (US$ Million)
 Table 46. Latin America Vaccine for Influenza Revenue by Country (2026-2031) & (US$ Million)
 Table 47. Middle East and Africa Vaccine for Influenza Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 48. Middle East and Africa Vaccine for Influenza Sales by Country (2020-2025) & (M Units)
 Table 49. Middle East and Africa Vaccine for Influenza Sales by Country (2026-2031) & (M Units)
 Table 50. Middle East and Africa Vaccine for Influenza Revenue by Country (2020-2025) & (US$ Million)
 Table 51. Middle East and Africa Vaccine for Influenza Revenue by Country (2026-2031) & (US$ Million)
 Table 52. Global Vaccine for Influenza Sales (M Units) by Type (2020-2025)
 Table 53. Global Vaccine for Influenza Sales (M Units) by Type (2026-2031)
 Table 54. Global Vaccine for Influenza Sales Market Share by Type (2020-2025)
 Table 55. Global Vaccine for Influenza Sales Market Share by Type (2026-2031)
 Table 56. Global Vaccine for Influenza Revenue (US$ Million) by Type (2020-2025)
 Table 57. Global Vaccine for Influenza Revenue (US$ Million) by Type (2026-2031)
 Table 58. Global Vaccine for Influenza Revenue Market Share by Type (2020-2025)
 Table 59. Global Vaccine for Influenza Revenue Market Share by Type (2026-2031)
 Table 60. Global Vaccine for Influenza Price (US$/Unit) by Type (2020-2025)
 Table 61. Global Vaccine for Influenza Price (US$/Unit) by Type (2026-2031)
 Table 62. Global Vaccine for Influenza Sales (M Units) by Application (2020-2025)
 Table 63. Global Vaccine for Influenza Sales (M Units) by Application (2026-2031)
 Table 64. Global Vaccine for Influenza Sales Market Share by Application (2020-2025)
 Table 65. Global Vaccine for Influenza Sales Market Share by Application (2026-2031)
 Table 66. Global Vaccine for Influenza Revenue (US$ Million) by Application (2020-2025)
 Table 67. Global Vaccine for Influenza Revenue (US$ Million) by Application (2026-2031)
 Table 68. Global Vaccine for Influenza Revenue Market Share by Application (2020-2025)
 Table 69. Global Vaccine for Influenza Revenue Market Share by Application (2026-2031)
 Table 70. Global Vaccine for Influenza Price (US$/Unit) by Application (2020-2025)
 Table 71. Global Vaccine for Influenza Price (US$/Unit) by Application (2026-2031)
 Table 72. Sanofi Company Information
 Table 73. Sanofi Description and Business Overview
 Table 74. Sanofi Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 75. Sanofi Vaccine for Influenza Product
 Table 76. Sanofi Recent Developments/Updates
 Table 77. CSL Company Information
 Table 78. CSL Description and Business Overview
 Table 79. CSL Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 80. CSL Vaccine for Influenza Product
 Table 81. CSL Recent Developments/Updates
 Table 82. GSK Company Information
 Table 83. GSK Description and Business Overview
 Table 84. GSK Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 85. GSK Vaccine for Influenza Product
 Table 86. GSK Recent Developments/Updates
 Table 87. Viatris Company Information
 Table 88. Viatris Description and Business Overview
 Table 89. Viatris Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 90. Viatris Vaccine for Influenza Product
 Table 91. Viatris Recent Developments/Updates
 Table 92. AstraZeneca Company Information
 Table 93. AstraZeneca Description and Business Overview
 Table 94. AstraZeneca Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 95. AstraZeneca Vaccine for Influenza Product
 Table 96. AstraZeneca Recent Developments/Updates
 Table 97. Hualan Bio Company Information
 Table 98. Hualan Bio Description and Business Overview
 Table 99. Hualan Bio Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 100. Hualan Bio Vaccine for Influenza Product
 Table 101. Hualan Bio Recent Developments/Updates
 Table 102. Changchun Institute of Biological Company Information
 Table 103. Changchun Institute of Biological Description and Business Overview
 Table 104. Changchun Institute of Biological Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 105. Changchun Institute of Biological Vaccine for Influenza Product
 Table 106. Changchun Institute of Biological Recent Developments/Updates
 Table 107. Sinovac Company Information
 Table 108. Sinovac Description and Business Overview
 Table 109. Sinovac Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 110. Sinovac Vaccine for Influenza Product
 Table 111. Sinovac Recent Developments/Updates
 Table 112. BCHT Company Information
 Table 113. BCHT Description and Business Overview
 Table 114. BCHT Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 115. BCHT Vaccine for Influenza Product
 Table 116. BCHT Recent Developments/Updates
 Table 117. Jiangsu GDK Company Information
 Table 118. Jiangsu GDK Description and Business Overview
 Table 119. Jiangsu GDK Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 120. Jiangsu GDK Vaccine for Influenza Product
 Table 121. Jiangsu GDK Recent Developments/Updates
 Table 122. KM Biologics Company Information
 Table 123. KM Biologics Description and Business Overview
 Table 124. KM Biologics Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 125. KM Biologics Vaccine for Influenza Product
 Table 126. KM Biologics Recent Developments/Updates
 Table 127. Key Raw Materials Lists
 Table 128. Raw Materials Key Suppliers Lists
 Table 129. Vaccine for Influenza Distributors List
 Table 130. Vaccine for Influenza Customers List
 Table 131. Vaccine for Influenza Market Trends
 Table 132. Vaccine for Influenza Market Drivers
 Table 133. Vaccine for Influenza Market Challenges
 Table 134. Vaccine for Influenza Market Restraints
 Table 135. Research Programs/Design for This Report
 Table 136. Key Data Information from Secondary Sources
 Table 137. Key Data Information from Primary Sources
 Table 138. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Vaccine for Influenza
 Figure 2. Global Vaccine for Influenza Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Vaccine for Influenza Market Share by Type: 2024 & 2031
 Figure 4. Trivalent Influenza Vaccine Product Picture
 Figure 5. Quadrivalent Influenza Vaccine Product Picture
 Figure 6. Global Vaccine for Influenza Market Value by Technology, (US$ Million) & (2020-2031)
 Figure 7. Global Vaccine for Influenza Market Share by Technology: 2024 VS 2031
 Figure 8. Chicken Embryo Technology Product Picture
 Figure 9. Cell Culture Technology Product Picture
 Figure 10. Recombinant Technology Product Picture
 Figure 11. Adjuvant Vaccines Product Picture
 Figure 12. Global Vaccine for Influenza Market Value by Administration, (US$ Million) & (2020-2031)
 Figure 13. Global Vaccine for Influenza Market Share by Administration: 2024 VS 2031
 Figure 14. Injectable Product Picture
 Figure 15. Nasal Spray Product Picture
 Figure 16. Global Vaccine for Influenza Market Value by Application (2020-2031) & (US$ Million)
 Figure 17. Global Vaccine for Influenza Market Share by Application: 2024 & 2031
 Figure 18. 6 Months to 3 Years
 Figure 19. > 3 Years
 Figure 20. Global Vaccine for Influenza Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 21. Global Vaccine for Influenza Market Size (2020-2031) & (US$ Million)
 Figure 22. Global Vaccine for Influenza Sales (2020-2031) & (M Units)
 Figure 23. Global Vaccine for Influenza Average Price (US$/Unit) & (2020-2031)
 Figure 24. Vaccine for Influenza Report Years Considered
 Figure 25. Vaccine for Influenza Sales Share by Manufacturers in 2024
 Figure 26. Global Vaccine for Influenza Revenue Share by Manufacturers in 2024
 Figure 27. Global 5 and 10 Largest Vaccine for Influenza Players: Market Share by Revenue in Vaccine for Influenza in 2024
 Figure 28. Vaccine for Influenza Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 29. Global Vaccine for Influenza Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 30. North America Vaccine for Influenza Sales Market Share by Country (2020-2031)
 Figure 31. North America Vaccine for Influenza Revenue Market Share by Country (2020-2031)
 Figure 32. United States Vaccine for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Canada Vaccine for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Europe Vaccine for Influenza Sales Market Share by Country (2020-2031)
 Figure 35. Europe Vaccine for Influenza Revenue Market Share by Country (2020-2031)
 Figure 36. Germany Vaccine for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. France Vaccine for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. U.K. Vaccine for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Italy Vaccine for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Russia Vaccine for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Asia Pacific Vaccine for Influenza Sales Market Share by Region (2020-2031)
 Figure 42. Asia Pacific Vaccine for Influenza Revenue Market Share by Region (2020-2031)
 Figure 43. China Vaccine for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Japan Vaccine for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. South Korea Vaccine for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. India Vaccine for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Australia Vaccine for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. China Taiwan Vaccine for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Southeast Asia Vaccine for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Latin America Vaccine for Influenza Sales Market Share by Country (2020-2031)
 Figure 51. Latin America Vaccine for Influenza Revenue Market Share by Country (2020-2031)
 Figure 52. Mexico Vaccine for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Brazil Vaccine for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Argentina Vaccine for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Middle East and Africa Vaccine for Influenza Sales Market Share by Country (2020-2031)
 Figure 56. Middle East and Africa Vaccine for Influenza Revenue Market Share by Country (2020-2031)
 Figure 57. Turkey Vaccine for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. Saudi Arabia Vaccine for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 59. UAE Vaccine for Influenza Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 60. Global Sales Market Share of Vaccine for Influenza by Type (2020-2031)
 Figure 61. Global Revenue Market Share of Vaccine for Influenza by Type (2020-2031)
 Figure 62. Global Vaccine for Influenza Price (US$/Unit) by Type (2020-2031)
 Figure 63. Global Sales Market Share of Vaccine for Influenza by Application (2020-2031)
 Figure 64. Global Revenue Market Share of Vaccine for Influenza by Application (2020-2031)
 Figure 65. Global Vaccine for Influenza Price (US$/Unit) by Application (2020-2031)
 Figure 66. Vaccine for Influenza Value Chain
 Figure 67. Channels of Distribution (Direct Vs Distribution)
 Figure 68. Bottom-up and Top-down Approaches for This Report
 Figure 69. Data Triangulation
 Figure 70. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Global Pandemic Influenza Vaccine Market Research Report 2025
Global Influenza Drugs and Vaccines Market Research Report 2025
Inactivated Influenza Vaccine Market
Influenza A Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Trivalent Inactivated Influenza Vaccine Market Research Report 2025
Global Inactivated Influenza Virus Vaccine Market Research Report 2025
Cell based Flu Vaccine Market
Needle Free Influenza Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Trivalent Flu Vaccine Market Insights Forecast to 2030
Global Quadrivalent Flu Vaccine Market Insights Forecast to 2030
Influenza Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Multivalent Influenza Vaccines Market Research Report 2025
Global Viral Vaccines Market Research Report 2025
Influenza Virus Vaccine H1N1 Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Injection Influenza Vaccine Market Research Report 2025
Swine Influenza Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Influenza Antiviral Drugs Market
Anti influenza Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cattle Vaccine Market Research Report 2025
Global Influenza Therapeutics Market Insights Forecast to 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions